| ID Source | ID |
|---|---|
| PubMed CID | 16194171 |
| CHEMBL ID | 1438370 |
| CHEBI ID | 121397 |
| Synonym |
|---|
| smr000310114 |
| MLS000660595 , |
| 2-[6-(2-fluorobenzyl)-5,7-dimethyl-1-oxo-1,6-dihydro-2h-pyrrolo[3,4-d]pyridazin-2-yl]-n-(2,3,5,6-tetrafluorophenyl)acetamide |
| CHEBI:121397 |
| AKOS001847570 |
| HMS2674F16 |
| MLS-0240691.0002 |
| MLS-0240691.0001 |
| MLS000660595-02 |
| SR-01000734658-2 |
| sr-01000734658 |
| 2-[6-(2-fluorobenzyl)-4-keto-5,7-dimethyl-pyrrolo[3,4-d]pyridazin-3-yl]-n-(2,3,5,6-tetrafluorophenyl)acetamide |
| 2-[6-[(2-fluorophenyl)methyl]-5,7-dimethyl-4-oxopyrrolo[3,4-d]pyridazin-3-yl]-n-(2,3,5,6-tetrafluorophenyl)acetamide |
| 2-[6-[(2-fluorophenyl)methyl]-5,7-dimethyl-4-oxidanylidene-pyrrolo[3,4-d]pyridazin-3-yl]-n-[2,3,5,6-tetrakis(fluoranyl)phenyl]ethanamide |
| cid_16194171 |
| 2-[6-[(2-fluorophenyl)methyl]-5,7-dimethyl-4-oxo-3-pyrrolo[3,4-d]pyridazinyl]-n-(2,3,5,6-tetrafluorophenyl)acetamide |
| bdbm48851 |
| CHEMBL1438370 |
| Q27209937 |
| Class | Description |
|---|---|
| anilide | Any aromatic amide obtained by acylation of aniline. |
| [compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res] | |
| Protein | Taxonomy | Measurement | Average (µ) | Min (ref.) | Avg (ref.) | Max (ref.) | Bioassay(s) |
|---|---|---|---|---|---|---|---|
| Chain A, MAJOR APURINIC/APYRIMIDINIC ENDONUCLEASE | Homo sapiens (human) | Potency | 39.8107 | 0.0032 | 45.4673 | 12,589.2998 | AID2517 |
| Chain A, JmjC domain-containing histone demethylation protein 3A | Homo sapiens (human) | Potency | 44.6684 | 0.6310 | 35.7641 | 100.0000 | AID504339 |
| Chain A, 2-oxoglutarate Oxygenase | Homo sapiens (human) | Potency | 39.8107 | 0.1778 | 14.3909 | 39.8107 | AID2147 |
| Chain A, ATP-DEPENDENT DNA HELICASE Q1 | Homo sapiens (human) | Potency | 13.0595 | 0.1259 | 19.1169 | 125.8920 | AID2549; AID504841 |
| glp-1 receptor, partial | Homo sapiens (human) | Potency | 28.1838 | 0.0184 | 6.8060 | 14.1254 | AID624417 |
| WRN | Homo sapiens (human) | Potency | 31.9253 | 0.1683 | 31.2583 | 100.0000 | AID651768; AID720497 |
| ATAD5 protein, partial | Homo sapiens (human) | Potency | 6.5104 | 0.0041 | 10.8903 | 31.5287 | AID504467 |
| USP1 protein, partial | Homo sapiens (human) | Potency | 35.4813 | 0.0316 | 37.5844 | 354.8130 | AID743255 |
| bromodomain adjacent to zinc finger domain 2B | Homo sapiens (human) | Potency | 56.2341 | 0.7079 | 36.9043 | 89.1251 | AID504333 |
| euchromatic histone-lysine N-methyltransferase 2 | Homo sapiens (human) | Potency | 39.8107 | 0.0355 | 20.9770 | 89.1251 | AID504332 |
| Bloom syndrome protein isoform 1 | Homo sapiens (human) | Potency | 8.2083 | 0.5406 | 17.6392 | 96.1227 | AID2528; AID720503 |
| DNA polymerase beta | Homo sapiens (human) | Potency | 6.3096 | 0.0224 | 21.0102 | 89.1251 | AID485314; AID540280 |
| flap endonuclease 1 | Homo sapiens (human) | Potency | 79.4328 | 0.1337 | 25.4129 | 89.1251 | AID588795 |
| serine/threonine-protein kinase PLK1 | Homo sapiens (human) | Potency | 16.8336 | 0.1683 | 16.4040 | 67.0158 | AID720504 |
| peptidyl-prolyl cis-trans isomerase NIMA-interacting 1 | Homo sapiens (human) | Potency | 39.8107 | 0.4256 | 12.0591 | 28.1838 | AID504891 |
| DNA polymerase eta isoform 1 | Homo sapiens (human) | Potency | 49.9653 | 0.1000 | 28.9256 | 213.3130 | AID588591; AID720502 |
| DNA polymerase iota isoform a (long) | Homo sapiens (human) | Potency | 23.8589 | 0.0501 | 27.0736 | 89.1251 | AID588590; AID720496 |
| DNA polymerase kappa isoform 1 | Homo sapiens (human) | Potency | 44.6684 | 0.0316 | 22.3146 | 100.0000 | AID588579 |
| survival motor neuron protein isoform d | Homo sapiens (human) | Potency | 0.1995 | 0.1259 | 12.2344 | 35.4813 | AID1458 |
| histone acetyltransferase KAT2A isoform 1 | Homo sapiens (human) | Potency | 16.5116 | 0.2512 | 15.8432 | 39.8107 | AID504327; AID588347 |
| Rap guanine nucleotide exchange factor 3 | Homo sapiens (human) | Potency | 39.8107 | 6.3096 | 60.2008 | 112.2020 | AID720709 |
| Phosphatidylinositol 5-phosphate 4-kinase type-2 alpha | Homo sapiens (human) | Potency | 10.0000 | 6.3096 | 15.3445 | 35.4813 | AID743286 |
| [prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023] | |||||||
| Protein | Taxonomy | Measurement | Average | Min (ref.) | Avg (ref.) | Max (ref.) | Bioassay(s) |
|---|---|---|---|---|---|---|---|
| PSMD14 protein | Homo sapiens (human) | IC50 (µMol) | 19.5000 | 1.3000 | 21.8715 | 50.9000 | AID602368 |
| Methyl-CpG binding domain protein 2 | Homo sapiens (human) | IC50 (µMol) | 12.3375 | 4.6950 | 4.6950 | 4.6950 | AID1053169; AID720645 |
| TPA: prothrombin | Bos taurus (cattle) | IC50 (µMol) | 50.5000 | 4.8100 | 36.7432 | 77.4000 | AID602369 |
| DNA (cytosine-5)-methyltransferase 1 isoform b | Homo sapiens (human) | IC50 (µMol) | 7.6000 | 1.2900 | 8.7555 | 41.0000 | AID602386 |
| 72 kDa type IV collagenase isoform 1 preproprotein | Homo sapiens (human) | IC50 (µMol) | 100.0000 | 5.7900 | 38.9633 | 78.4000 | AID602361 |
| eukaryotic translation initiation factor 4 gamma 1 isoform 4 | Homo sapiens (human) | IC50 (µMol) | 50.0000 | 1.1500 | 12.6200 | 25.6529 | AID855 |
| eukaryotic translation initiation factor 4E isoform 1 | Mus musculus (house mouse) | IC50 (µMol) | 50.0000 | 1.1500 | 12.6200 | 25.6529 | AID855 |
| carboxy-terminal domain RNA polymerase II polypeptide A small phosphatase 1 isoform 1 | Homo sapiens (human) | IC50 (µMol) | 2.9570 | 2.0580 | 8.2052 | 41.3880 | AID540297 |
| DNA dC->dU-editing enzyme APOBEC-3G isoform 1 | Homo sapiens (human) | IC50 (µMol) | 9.3100 | 0.2700 | 26.3638 | 100.0000 | AID504719 |
| DNA dC->dU-editing enzyme APOBEC-3A isoform a | Homo sapiens (human) | IC50 (µMol) | 49.3000 | 1.4800 | 14.5267 | 61.2000 | AID504722 |
| [prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023] | |||||||
| Process | via Protein(s) | Taxonomy |
|---|---|---|
| guanyl-nucleotide exchange factor activity | Rap guanine nucleotide exchange factor 3 | Homo sapiens (human) |
| protein binding | Rap guanine nucleotide exchange factor 3 | Homo sapiens (human) |
| protein domain specific binding | Rap guanine nucleotide exchange factor 3 | Homo sapiens (human) |
| cAMP binding | Rap guanine nucleotide exchange factor 3 | Homo sapiens (human) |
| protein binding | Phosphatidylinositol 5-phosphate 4-kinase type-2 alpha | Homo sapiens (human) |
| ATP binding | Phosphatidylinositol 5-phosphate 4-kinase type-2 alpha | Homo sapiens (human) |
| 1-phosphatidylinositol-4-phosphate 5-kinase activity | Phosphatidylinositol 5-phosphate 4-kinase type-2 alpha | Homo sapiens (human) |
| 1-phosphatidylinositol-5-phosphate 4-kinase activity | Phosphatidylinositol 5-phosphate 4-kinase type-2 alpha | Homo sapiens (human) |
| protein homodimerization activity | Phosphatidylinositol 5-phosphate 4-kinase type-2 alpha | Homo sapiens (human) |
| [Information is prepared from geneontology information from the June-17-2024 release] | ||
| Assay ID | Title | Year | Journal | Article |
|---|---|---|---|---|
| AID588501 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set | 2010 | Current protocols in cytometry, Oct, Volume: Chapter 13 | Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening. |
| AID588501 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set | 2006 | Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5 | Microsphere-based protease assays and screening application for lethal factor and factor Xa. |
| AID588501 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set | 2010 | Assay and drug development technologies, Feb, Volume: 8, Issue:1 | High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors. |
| AID504810 | Antagonists of the Thyroid Stimulating Hormone Receptor: HTS campaign | 2010 | Endocrinology, Jul, Volume: 151, Issue:7 | A small molecule inverse agonist for the human thyroid-stimulating hormone receptor. |
| AID1745845 | Primary qHTS for Inhibitors of ATXN expression | |||
| AID588499 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set | 2010 | Current protocols in cytometry, Oct, Volume: Chapter 13 | Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening. |
| AID588499 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set | 2006 | Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5 | Microsphere-based protease assays and screening application for lethal factor and factor Xa. |
| AID588499 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set | 2010 | Assay and drug development technologies, Feb, Volume: 8, Issue:1 | High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors. |
| AID588497 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set | 2010 | Current protocols in cytometry, Oct, Volume: Chapter 13 | Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening. |
| AID588497 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set | 2006 | Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5 | Microsphere-based protease assays and screening application for lethal factor and factor Xa. |
| AID588497 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set | 2010 | Assay and drug development technologies, Feb, Volume: 8, Issue:1 | High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors. |
| AID504812 | Inverse Agonists of the Thyroid Stimulating Hormone Receptor: HTS campaign | 2010 | Endocrinology, Jul, Volume: 151, Issue:7 | A small molecule inverse agonist for the human thyroid-stimulating hormone receptor. |
| AID651635 | Viability Counterscreen for Primary qHTS for Inhibitors of ATXN expression | |||
| [information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||||
| Timeframe | Studies, This Drug (%) | All Drugs % |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (20.00) | 29.6817 |
| 2010's | 3 (60.00) | 24.3611 |
| 2020's | 1 (20.00) | 2.80 |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||
According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be weak demand-to-supply ratio for research on this compound.
| This Compound (12.56) All Compounds (24.57) |
| Publication Type | This drug (%) | All Drugs (%) |
|---|---|---|
| Trials | 0 (0.00%) | 5.53% |
| Reviews | 0 (0.00%) | 6.00% |
| Case Studies | 0 (0.00%) | 4.05% |
| Observational | 0 (0.00%) | 0.25% |
| Other | 5 (100.00%) | 84.16% |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||